References
- Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, DeLisi C, Harris L, Barnard N, Martel M, Levine AJ et al. High expression of lymphocyte-associated genes in node-negative HER2pos breast cancers correlates with lower recurrence rates. Cancer Res 2007; 67:10669-76; https://doi.org/10.1158/0008-5472.CAN-07-0539
- Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol 2015; 33:701-8; PMID:25605861; https://doi.org/10.1200/JCO.2014.57.6298
- Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic A, Ponniah S et al. Clinical trial results of the HER2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2012; 118:2594-602; PMID:21989902; https://doi.org/10.1002/cncr.26574
- Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 1998; 58:4902-8; PMID:9809997
- Mimura K, Ando T, Poschke I, Mougiakakos D, Johansson CC, Ichikawa J, Okita R, Nishimura MI, Handke D, Krug N et al. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer 2011; 128:390-401; PMID:20715101; https://doi.org/10.1002/ijc.25613
- Datta J, Xu S, Rosemblit C, Smith JB, Cintolo JA, Powell DJ, Jr., Czerniecki BJ. CD4+ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8+ T-cell Targeting of HER2/neu-Expressing Cancers. Cancer Immunol Res 2015; 3:455-63; PMID:25791067; https://doi.org/10.1158/2326-6066.CIR-14-0208
- Lollini PL, Nicoletti G, Landuzzi L, De Giovanni C, Rossi I, Di Carlo E, Musiani P, Muller WJ, Nanni P. Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. Int J Cancer 1998; 77:937-41; PMID:9714068; https://doi.org/10.1002/(SICI)1097-0215(19980911)77:6%3c937::AID-IJC24%3e3.0.CO;2-X
- Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One 2014; 9:e88557; PMID:24551119; https://doi.org/10.1371/journal.pone.0088557
- Datta J, Berk E, Rosemblit C, Showalter S, Mick R, Lee KP, Brod AM, Yang RL, Kelz RR, Fitzpatrick E et al. Progressive Loss of Anti-HER2 CD4+ T-helper Type 1 Response during Breast Tumorigenesis and the Potential for Immune Restoration. OncoImmunology 2015
- Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld L, Goodman N, Lewis DA, Zhang PJ, Fisher C et al. Anti-HER2 CD4 T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer. Breast Cancer Res 2015; 17:71; PMID:25997452; https://doi.org/10.1186/s13058-015-0584-1